2 recruiting, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow olpasiran: new trials by email Literature Review of olpasiran trials Research Report on olpasiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial Olpasiran, Placebo - Cardiovascular Disease | Phase 3 | Recruiting | Amgen | 406 | 2026-03-23 | 2026-04-16 |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events Olpasiran, Placebo - Cardiovascular Disease | Phase 3 | Recruiting | Amgen | 11000 | 2025-08-22 | 2026-11-16 |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Placebo, Olpasiran - Atherosclerotic Cardiovascular Disease | Phase 3 | Active not recruiting | Amgen | 7297 | 2022-12-14 | 2026-10-27 |
Cardiovascular Diseases (2) · Atherosclerosis (1) · Coronary Disease (1) · Myocardial Infarction (1)
Amgen (3)
Australia (3) · China (3) · United States (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Estonia (1)
PMID 38415744, PMID 38682459, PMID 39322524, PMID 39329200, PMID 41329869, PMID 41841810